Key result
Multiple drug use (≥5 drugs) at discharge independently increased the risk of all-cause mortality or heart failure readmission by 36% compared to non-multiple drug use in patients hospitalized with heart failure.
Why the study?
The association between polypharmacy or multiple drug use (MDU) and prognosis in patients hospitalized with HF was unclear, as was whether its prognostic value varies by prior HF history or preserved versus reduced LVEF.
Does multiple drug use (≥5 drugs) at discharge increase the risk of all-cause mortality or heart failure readmission in patients hospitalized with heart failure?
Cohort (n=1,034)
No
Does multiple drug use (≥5 drugs) at discharge increase the risk of all-cause mortality or heart failure readmission in patients hospitalized with heart failure?
Multiple drug use (≥5 drugs) at discharge is an independent risk factor for the composite of death or heart failure readmission in patients hospitalized with heart failure, particularly in those with a prior history of heart failure.
Answers are grounded in this paper and cite their sources.
MDU at discharge signals higher composite risk in hospitalized HF; leaves open whether deprescribing improves outcomes in this population.
The association between polypharmacy/multiple drug use (MDU) and prognosis in patients hospitalized with heart failure (HF) is unclear. It is also unknown whether the prognostic values of MDU vary depending on the presence/absence of a previous history of HF and preserved/reduced left ventricular ejection fraction (LVEF). We analyzed consecutive 1,034 patients hospitalized with HF (age, 74.9 ± 11.5 years; 58.7% male). MDU was defined as ≥5 drugs at discharge. The primary endpoint was a composite of all-cause death and HF readmission. MDU was observed in 695 patients (67.2%). Patients with MDU use had higher prevalences of a previous history of HF, reduced LVEF, and comorbidities than those without MDU. Cox proportional hazard analysis showed that MDU was significantly associated with the primary endpoint after adjustment for possible confounders (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.03-1.79; P = 0.030). There was significant interaction between the presence/absence of a history of HF and the prognostic impact of MDU (HF history [-]: HR, 0.86; 95% CI, 0.54-1.40; P = 0.553; HF history [+]: HR, 1.72; 95% CI, 1.16-2.55; P = 0.007; P for interaction = 0.005). However, there was no significant interaction between preserved/reduced LVEF and the prognostic impact of MDU (P for interaction = 0.274). In conclusion, MDU at discharge is an independent risk factor for the composite of death or HF readmission in patients hospitalized with HF. We observed a significant interaction between the presence of de novo versus recurrent HF and the prognostic value of MDU.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2023) conducted a cohort in Heart Failure (n=1,034). Multiple drug use (≥5 drugs) at discharge vs. Non-multiple drug use (<5 drugs) at discharge was evaluated on Composite of all-cause mortality and heart failure readmission (HR 1.36, 95% CI 1.03-1.79, p=0.030). Multiple drug use (≥5 drugs) at discharge independently increased the risk of all-cause mortality or heart failure readmission by 36% compared to non-multiple drug use in patients hospitalized with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: